Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Effects of GLP-1 receptor agonists on kidney and cardiovascular outcomes: meta-analysis
Farxiga (dapagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease
Researchers scanning the brains of adolescents on GLP1 treatment have reported changes in connectivity networks that govern what we notice and care about, not just what we crave
Effective risk mitigation must prioritize the safety of at-risk populations, including individuals who are immunocompromised and those with significant comorbidities
Redox regulation of mitochondrial ATP synthase
US$ 20.11
US$ 23.62
US$ 29.70
